Pusztai, Lajos
Yale Cancer Center · Yale University
15 papers on CoChatORCID 0000-0001-9632-6686
Most cited papers
- Verified
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine
Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers
Cited by 3,270
- Verified
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology
Breast Cancer Treatment StudiesBreast Lesions and Carcinomas
Cited by 2,892
- Verified
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology
Cancer Genomics and DiagnosticsGenomics and Rare Diseases
Cited by 2,157
- Verified
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
MAQC Consortium, Shi, L., Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., et al. (2006) · Nature Biotechnology
Gene expression and cancer classificationMolecular Biology Techniques and Applications
Cited by 2,126
- Verified
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies
Cited by 1,477
- Verified
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research
PI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies
Cited by 1,054
- Verified
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine
interferon and immune responsesImmunotherapy and Immune Responses
Cited by 1,042
- Verified
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology
Breast Cancer Treatment StudiesCancer Treatment and Pharmacology
Cited by 710
- Verified
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research
Estrogen and related hormone effectsAdvanced Breast Cancer Therapies
Cited by 674
- Verified
Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
Ayers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., et al. (2004) · Journal of Clinical Oncology
Breast Cancer Treatment StudiesGene expression and cancer classification
Cited by 566
- Verified
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
Iwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., Ueno, N. T., Zhang, J., Shi, W., Qi, Y., et al. (2012) · Journal of Clinical Oncology
Breast Cancer Treatment StudiesEstrogen and related hormone effects
Cited by 288
- Verified
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre, F., & Pusztai, L. (2006) · Nature Clinical Practice Oncology
Breast Cancer Treatment StudiesGene expression and cancer classification
Cited by 134
- Verified
Evaluation of large language models as a diagnostic aid for complex medical cases
Ríos-Hoyo, A., Shan, N. L., Li, A., Pearson, A. T., Pusztai, L., & Howard, F. M. (2024) · Frontiers in Medicine
Artificial Intelligence in Healthcare and EducationArtificial Intelligence in Healthcare
Cited by 66
- Verified
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers
Coutant, C., Rouzier, R., Qi, Y., Lehmann-Che, J., Bianchini, G., Iwamoto, T., Hortobagyi, G. N., Symmans, W. F., Uzan, S., Andre, F., et al. (2011) · Clinical Cancer Research
Breast Cancer Treatment StudiesCancer-related Molecular Pathways
Cited by 64
- Verified
Increased epigenetic age in normal breast tissue from luminal breast cancer patients
Hofstatter, E. W., Horvath, S., Dalela, D., Gupta, P., Chagpar, A. B., Wali, V. B., Bossuyt, V., Storniolo, A. M., Hatzis, C., Patwardhan, G., et al. (2018) · Clinical Epigenetics
Epigenetics and DNA MethylationTelomeres, Telomerase, and Senescence
Cited by 64
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free